Short answer: Clinical trials of approved metabolic medicines such as semaglutide and tirzepatide show group averages and real differences between people, but they cannot justify a "personalised protocol" built on a separately made research peptide. A trial validates one product, one population and one level of oversight; a model of individual variation is a research tool, not personal guidance.
The internet has a favourite move. Take a big, well-run trial of an approved drug, borrow its results, and slap them on a research vial with a similar name and a "personalised protocol". It sounds scientific. It is not. Here is what metabolic research can and cannot tell you.
Peptide-related metabolic research looks at receptor signalling linked to appetite, blood sugar control and energy balance. Those pathways sit inside a wider system shaped by genetics, health, behaviour, environment and the conditions of each study.
Because everything is connected, it is tempting to describe a pathway as a simple lever. The published literature does not support that. Different molecules, formulations, populations and endpoints produce different results, even when they appear to act on related receptors. A pathway is a question to investigate, not a promise about your body.
Large randomised trials tested specific, regulated medicines in defined adult populations: Wilding and colleagues reported a semaglutide trial in 2021, and Jastreboff and colleagues a tirzepatide trial in 2022. On our scale those results are grade A, for those products, in those populations.
They do not validate separately manufactured research compounds, retail material or unapproved alternatives. A similar name does not mean equivalent manufacturing, formulation, quality control or legal status. A paper is not a quality certificate for material its authors never touched. Our graded peptides hub keeps that line visible: every grade belongs to one claim, one product and one population.
No. A 2019 review by Brown and colleagues explains why responses to some metabolic drug classes vary between people. That variation is real and worth studying. It does not mean any one person's response can be predicted accurately.
Strathe and colleagues built a model in 2023 to predict individual weight loss on semaglutide using trial data. Useful for testing hypotheses and designing studies. Its conclusions depend on the population, data quality, assumptions and the specific medicine it was built on. It is not an instruction set, and it cannot turn an unapproved material into a personalised treatment.
What actually tells you how you respond is your own data, measured before and after under proper supervision. That is why we start with bloodwork: see the bloodwork guide or the bloodwork hub.
A 2022 extension of the STEP 1 trial followed people after semaglutide was stopped and documented weight regain and changes in cardiometabolic markers. One endpoint is not a whole trajectory. Follow-up length, retention, background care and the timing of measurements all shape a result, and a group average can hide wide individual spread. Short windows make bad promises.
No. Reviews bring trials together but do not erase their differences. A 2025 review by Moiz and colleagues in the Annals of Internal Medicine noted important differences between randomised trials of GLP-1 receptor agonists for weight loss in adults without diabetes and found no direct head-to-head randomised comparisons for the products discussed. That limits what can be said about which works better. It says nothing at all about research material bought online.
No. The US FDA has warned about unapproved GLP-1 products sold for weight management and is clear that "research use only" or "not for human consumption" wording does not fix marketing that otherwise signals human use. In the EU, a product presented for human use is a medicine under Directive 2001/83/EC and needs a marketing authorisation; regulators such as the IGJ in the Netherlands, AEMPS in Spain and BfArM in Germany act on that basis. Country detail: Netherlands, Spain, Germany and Austria.
Real personalisation is not a ready-made protocol. It is your own baseline, one change at a time, a retest, and a doctor where a medicine is involved. If that is the standard you want, take the 2-minute check or look at coaching.
No. A trial establishes evidence for the specific regulated product, form, population and oversight in its protocol. It says nothing about the identity, purity, formulation or legal status of a separately manufactured research material.
That people respond differently within the same study. It does not mean an individual's response can be predicted, and it does not support personalised protocols built on unapproved material.
Short studies capture early responses. Longer follow-up can show plateaus or regain after stopping, as the STEP 1 extension did. The time frame is part of the evidence.
No. In the EU a product presented for human use is a medicine and needs a marketing authorisation. A research-use statement does not change that.
Measure. A baseline before any change, one change at a time, and a retest. Our bloodwork guide shows where to start.
Education, not medical advice. This article discusses published research only and gives no treatment plans. Research materials are not authorised medicines.